Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PREDNISONE vs ACETIC ACID W/ HYDROCORTISONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Allergic reactions (severe or incapacitating),Asthma,Chronic obstructive pulmonary disease (COPD) exacerbation,Collagen diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis),Dermatologic diseases (e.g., pemphigus, severe erythema multiforme),Endocrine disorders (e.g., adrenocortical insufficiency, congenital adrenal hyperplasia),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura),Neoplastic diseases (e.g., leukemias, lymphomas),Nephrotic syndrome,Ophthalmic diseases (e.g., severe allergic conjunctivitis, keratitis),Organ transplantation (immunosuppression),Respiratory diseases (e.g., sarcoidosis, berylliosis),Rheumatic disorders (e.g., acute gouty arthritis, psoriatic arthritis),Tuberculous meningitis (with appropriate antituberculous therapy)
Treatment of superficial bacterial infections of the external auditory canal (otitis externa) and associated inflammation.
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Acetic acid: not applicable; hydrocortisone: plasma half-life ~1.5 hours (biologic half-life 8–12 hours). Due to low systemic absorption from topical application, systemic half-life is clinically irrelevant.
Hepatic, primarily via CYP3A4-mediated 6β-hydroxylation; also reduced by 20-ketosteroid reductases. Prednisone is a prodrug converted to active metabolite prednisolone.
Acetic acid is metabolized via the Krebs cycle to carbon dioxide and water. Hydrocortisone is primarily metabolized in the liver.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Acetic acid: minimal systemic absorption; hydrocortisone: hepatic metabolism, renal excretion of metabolites (<5% unchanged). Less than 10% of applied dose excreted in urine as metabolites; biliary/fecal excretion negligible.
Prednisone: 70-90% bound to albumin and corticosteroid-binding globulin (CBG); prednisolone: 60-70% bound.
Hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid: negligible binding.
Vd: 0.5-1.0 L/kg; distributes widely, crosses placenta and enters breast milk; apparent Vd larger with hyperthyroidism.
Hydrocortisone: Vd ~0.3–0.5 L/kg (systemic); topical application results in negligible systemic distribution.
Oral: 70-80% (active prednisolone after hepatic conversion); IM: ~100%.
Topical: ~1–5% of hydrocortisone absorbed through intact skin; higher with inflamed skin or occlusion. Acetic acid: negligible systemic absorption.
No dose adjustment required for renal impairment; consider alternative corticosteroid in severe renal disease if fluid retention is a concern.
No dose adjustment required for acetic acid. Hydrocortisone is minimally affected by renal impairment; no specific adjustment recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: use with caution; dose reduction may be considered due to decreased clearance; monitor for adverse effects.
No dose adjustment required for acetic acid. For hydrocortisone, use with caution in severe hepatic impairment (Child-Pugh C) due to reduced metabolism; consider reducing frequency or dose, though no specific guidelines exist.
0.1-2 mg/kg/day orally divided 1-4 times daily; maximum 60 mg/day; use lowest effective dose; for acute asthma, 1-2 mg/kg/day for 3-5 days.
Safety and efficacy not established in pediatric patients; use not recommended.
Start at lower end of dosing range (5-7.5 mg/day) due to increased risk of osteoporosis, hyperglycemia, and infections; monitor glucose and bone density; taper slowly to avoid adrenal suppression.
No specific dose adjustment required. Use caution due to potential skin atrophy and systemic absorption; limit duration to minimum effective course.
None
Not applicable.
Adrenal suppression and HPA axis suppression with prolonged therapy,Increased risk of infections,Exacerbation of systemic fungal infections,Masking of signs of infection,Osteoporosis with long-term use,Gastrointestinal perforation (especially in patients with certain GI disorders),Kaposi sarcoma reported,Cardiovascular effects (hypertension, fluid retention),Behavioral disturbances (euphoria, depression, psychosis),Posterior subcapsular cataracts and glaucoma,Thromboembolism risk,Vaccine response may be diminished; live vaccines contraindicated
For otic use only; not for ophthalmic or systemic use.,Prolonged use may lead to fungal or bacterial superinfection.,Discontinue if irritation or sensitization develops.
Systemic fungal infections,Hypersensitivity to prednisone or any component,Administration of live or live attenuated vaccines (due to immunosuppression)
Hypersensitivity to any component.,Viral or fungal infections of the external ear (e.g., herpes simplex, varicella).,Perforated tympanic membrane (risk of ototoxicity).
Avoid grapefruit juice as it may increase prednisone levels. Limit high-sodium foods to prevent fluid retention. Increase calcium and vitamin D intake to counteract bone loss. Avoid alcohol due to added GI irritation risk.
No clinically relevant food interactions. No specific dietary restrictions.
First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose-dependent fetal hypothalamic-pituitary-adrenal axis suppression.
Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed with topical use. Systemic absorption is minimal with small-area application. Avoid prolonged use on large areas, occlusive dressings, or high-potency steroids. Acetic acid has no known teratogenic risk.
Prednisone enters breast milk in low concentrations (M/P ratio ~0.25-0.5). Maternal doses ≤20 mg/day produce negligible infant exposure. Higher doses: Avoid breastfeeding for 4 hours after dose. Monitor infant for growth and adrenal suppression.
Minimal systemic absorption of topical hydrocortisone and acetic acid; unlikely to affect the breastfed infant. Use on limited areas, avoid application to breast or nipple area. M/P ratio not established.
Minimal pharmacokinetic changes (slight increase in clearance). No routine dose adjustment needed. For acute indications, use lowest effective dose. For chronic conditions, increase dose may be needed in third trimester due to disease flare; taper postpartum.
No dosing adjustments required for pregnancy. Use lowest effective dose for shortest duration to minimize systemic absorption.
Prednisone is a prodrug converted to prednisolone; use prednisolone in severe hepatic impairment. Taper dose after prolonged use (≥3 weeks) to avoid adrenal crisis. Morning dosing mimics cortisol rhythm and reduces insomnia. Monitor for hyperglycemia, osteoporosis, avascular necrosis, and immunosuppression. Do not give live vaccines during therapy.
Combination otic suspension for external otitis. Ensure tympanic membrane is intact before use; perforation risks ototoxicity. Shake well before instillation. Use for no longer than 10 days to avoid fungal overgrowth or adrenal suppression. Warm bottle in hands to avoid caloric vertigo. Contraindicated in viral or fungal infections of the ear canal.
Take with food or milk to reduce stomach upset.,Do not stop abruptly; follow a tapering schedule from your doctor.,Notify your doctor if you experience fever, unusual bleeding, or weight gain.,Avoid live vaccines (e.g., MMR, nasal flu) while on prednisone.,Carry a steroid alert card or wear a medical ID bracelet.
For ear use only. Do not swallow or put in eyes.,Lie on side with affected ear upward for 5 minutes after instillation.,Keep ear clean and dry while using the medication.,Complete full course even if symptoms improve.,Do not use if you have a perforated eardrum; seek medical evaluation first.,Shake the bottle well before each use.
"The combination of Droxicam, a nonsteroidal anti-inflammatory drug (NSAID) with potent COX-1/COX-2 inhibition, and the corticosteroid Prednisone results in an additive risk of gastrointestinal (GI) mucosal injury and bleeding. NSAIDs suppress protective prostaglandin synthesis in the gastric mucosa via COX-1 inhibition, while corticosteroids further impair mucosal defense and repair mechanisms, increasing the likelihood of peptic ulceration, GI perforation, and hemorrhage. Patients, particularly the elderly or those with prior GI disease, face a significantly elevated risk of serious adverse outcomes including upper GI bleeding and perforation."
"Cabergoline, a dopamine receptor agonist, can cause valvular heart disease due to its agonistic activity at serotonin 5-HT2B receptors on cardiac valves, leading to fibrotic changes. Prednisone, a corticosteroid, may potentiate this risk by suppressing inflammatory responses that could otherwise mitigate fibrotic progression, and by inducing catabolic effects that may exacerbate tissue vulnerability. Concurrent use may therefore increase the severity and progression of valvulopathy and other fibrotic complications."
"Concomitant use of Suprofen, a nonsteroidal anti-inflammatory drug (NSAID), with Prednisone, a corticosteroid, increases the risk of gastrointestinal (GI) adverse effects, including ulceration, bleeding, and perforation. This additive effect results from synergistic inhibition of prostaglandin-mediated protective mechanisms in the gastric mucosa, as both drug classes suppress COX enzymes and reduce mucosal defense. Patients, especially the elderly or those with a history of peptic ulcer disease, are at heightened risk for serious GI complications."
"Hydrocortisone, a corticosteroid, may inhibit the hepatic metabolism of doxycycline, a tetracycline antibiotic, leading to increased doxycycline plasma concentrations. This elevation can potentiate doxycycline's adverse effects, such as gastrointestinal disturbance, photosensitivity, and hepatotoxicity. Clinically, this interaction may reduce the therapeutic window of doxycycline, requiring dose adjustment or alternative therapy selection."
"Fluconazole, a potent inhibitor of cytochrome P450 3A4 (CYP3A4), can significantly reduce the hepatic clearance of hydrocortisone, a corticosteroid metabolized primarily by CYP3A4. This interaction leads to increased systemic exposure to hydrocortisone, potentially resulting in exaggerated corticosteroid effects such as hyperglycemia, immunosuppression, and adrenal suppression. Clinically, patients may experience symptoms of Cushing's syndrome or require dose adjustments to avoid toxicity."
"Rifaximin, a non-systemic antibiotic primarily acting in the gastrointestinal tract, may inhibit intestinal P-glycoprotein (P-gp), reducing the efflux of corticosteroids like hydrocortisone. This can lead to increased systemic absorption and elevated serum concentrations of hydrocortisone, potentially enhancing both therapeutic and adverse effects such as hyperglycemia, immunosuppression, and adrenal suppression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PREDNISONE vs ACETIC ACID W/ HYDROCORTISONE, answered by our medical review team.
PREDNISONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.. ACETIC ACID W/ HYDROCORTISONE is a Corticosteroid that works by Acetic acid exerts antibacterial and antifungal activity by lowering p H and disrupting microbial cell membranes. Hydrocortisone is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PREDNISONE and ACETIC ACID W/ HYDROCORTISONE depend on the specific clinical indication. These are both Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PREDNISONE is: 5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.. The standard adult dose of ACETIC ACID W/ HYDROCORTISONE is: 1 applicatorful (approximately 5 g) of the cream or ointment (containing 2% acetic acid and 1% hydrocortisone) inserted intravaginally once or twice daily for 7 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PREDNISONE and ACETIC ACID W/ HYDROCORTISONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PREDNISONE is classified as Category D/X. First trimester: Increased risk of cleft lip/palate (odds ratio 1.3-3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, preterm delivery. Chronic use: Dose. ACETIC ACID W/ HYDROCORTISONE is classified as Category D/X. Topical corticosteroids are generally considered low risk in pregnancy. Hydrocortisone is a weak corticosteroid. No increased risk of congenital malformations has been observed wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.